Legal Representation
Attorney
John M. Murphy
USPTO Deadlines
Next Deadline
588 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2021-03-16)
Due Date
March 16, 2027
Grace Period Ends
September 16, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
31 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Jan 15, 2024 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
Jan 15, 2024 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
Jan 15, 2024 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
Jan 15, 2024 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
Jan 15, 2024 | ECDR | I | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | Loading... |
Jan 15, 2024 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
Jul 12, 2023 | WOAG | I | WITHDRAWAL OF ATTORNEY GRANTED | Loading... |
Jul 12, 2023 | WOAR | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED | Loading... |
Mar 16, 2021 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
Dec 29, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
Dec 29, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
Dec 9, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
Nov 24, 2020 | PBCR | Z | WITHDRAWN FROM PUB - OG REVIEW QUERY | Loading... |
Nov 10, 2020 | FIXD | O | ELECTRONIC RECORD REVIEW COMPLETE | Loading... |
Oct 30, 2020 | ERRR | O | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | Loading... |
Oct 27, 2020 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Oct 26, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
Oct 26, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
Oct 26, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Jul 15, 2020 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
Jul 15, 2020 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
Jul 15, 2020 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Jun 23, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Jun 22, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
Jun 22, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
Jun 18, 2020 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
Jun 18, 2020 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
Jun 18, 2020 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Jun 15, 2020 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Mar 26, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Mar 26, 2020 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Medicines and pharmaceutical preparations, namely, pharmaceutical and medicinal products for ophthalmic use, antipyretics, analgesics, anesthetics, antiallergic medicines, antihistamines, antidotes, arsenic detoxification agents for medical purposes, benzol detoxification agents for medical purposes, chlorine detoxification agents for medical purposes, opium alkaloid preparations, smoking cessation preparations, pharmaceutical preparations, namely, antineoplastic and immunomodulating agents, anti-cancer preparations, anti-arthritic compositions and preparations, antiphlogistic analgesics, anti-rheumatic, pharmaceutical preparations for inhalation for the treatment of pulmonary hypertensions, antitussives, expectorants, inhalant anesthetics, cardiovascular treatment preparations, analeptics, pharmaceutical preparations for treating hypertension, antibacterial pharmaceuticals, pharmaceutical preparations for the treatment of heart rhythm disorders, antihypertensives, vasodilators, chemotherapeutics, antibiotic preparations, antifungal preparations, anti-tuberculous preparations, anti-leprotic agents, anti-protozoa preparations, medicinal preparations used in the treatment of malaria, antivirals, antiparasitic preparations, dermatological pharmaceutical products, antiparasitic preparations, dermatologics, radio-isotope markers for therapeutic or diagnostic use, dietary supplements, disinfectants, diuretics and anti-diuretics, antianemia drugs, anticoagulants, preparations for transfusions, enzymes for medical purposes, enzyme inhibitors, nutraceuticals for use as a dietary supplement for liver support, medicines for treatment of gastrointestinal diseases, antacids, diarrhea medication, anthelmintics, emetics, anti-emetic pharmaceutical preparations, medicated mouthwash for treating ulcers, antiflatulents, digestives for pharmaceutical purposes, medicines for use in indigestion, anti-inflammatories, laxatives, antiseptics, pharmaceutical preparations for the treatment and prevention of women's disorders and diseases, specifically, pharmaceutical preparations for assisted reproductive therapy, pharmaceutical preparations for the prevention and treatment of luteal phase defects and the prevention of miscarriages, immunosuppressants, dietary and nutritional supplements for anabolic use, antidiabetic preparations, dietary and nutritional supplements used for weight loss, pharmaceutical preparations for the treatment of anorexia; pharmaceutical agents affecting metabolism, pharmaceutical preparations for the treatment of Parkinson's disease, hypnotic sedatives, neuroleptics, tranquilizers, antidepressants, anti-psychotic pharmaceutical preparations, analeptics, neuropathical agents and other neurotropic agents, hormones for medical purposes, poly-opotherapeutic curative preparations for postponing manifestations of aging, estrogen preparations, progestogens, contraceptive preparations, androgen preparations, anti-hormone drugs, otorhinolaryngological preparations, otorhinolaryngological serums, vaccines, antispasmodics, vitamins, dietary and nutritional supplements containing coenzyme q10, multivitamin preparations, pharmaceutical preparations for sublingual use for treatment of heart problems; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders
Additional Information
Design Mark
The mark consists of the word "SANFER" in stylized form.
Classification
International Classes
005